Nikolai Tankovich
About Nikolai Tankovich
Nikolai Tankovich is the President and Chief Medical Officer who holds both an MD and a PhD, and has co-authored several publications on the use of mesenchymal stem cells in treating various severe conditions.
Nikolai Tankovich - President and Chief Medical Officer
Nikolai Tankovich serves as the President and Chief Medical Officer. In his dual role, he is responsible for overseeing medical operations and guiding the organization’s strategic direction. His position involves significant leadership responsibilities and influence over company policies and procedures.
Nikolai Tankovich MD and PhD
Nikolai Tankovich holds both an MD and a PhD, emphasizing his extensive educational background and expertise in the medical field. His dual qualifications provide a strong foundation for his research and leadership activities, informing his approach to medical innovation and patient care.
Nikolai Tankovich Publications on COVID-19 Treatment
Nikolai Tankovich has co-authored publications on the treatment of severe COVID-19 using mesenchymal stem cells. These publications contribute to the body of knowledge on innovative treatments for severe cases of COVID-19, demonstrating the potential for stem cell therapy in combating the virus.
Research on Mesenchymal Stem Cells in Chronic Stroke by Nikolai Tankovich
Nikolai Tankovich has co-authored studies on the safety and efficacy of mesenchymal stem cells in chronic stroke. His research in this area explores the potential of stem cell therapy to improve outcomes for patients suffering from chronic stroke, providing insights into new treatment modalities.
Impact of Stem Cells on Alzheimer's Disease - Nikolai Tankovich's Research
Nikolai Tankovich has investigated the impact of mesenchymal stem cells on amyloid-beta pathology in Alzheimer's disease. Through his co-authored publications, he has contributed to understanding how stem cells may influence the progression of Alzheimer's, potentially offering new avenues for treatment.